AFP and liver cancer: When requiring >95% specificity in the HDs of the training set (specificity: 96.2%), the model accurately predicted the identity of all AFP-positive patients (sensitivity: 100%) and discriminated liver cancer patients from most CHB patients (specificity: 91.7%) (Figure 7B).